Abbott Laboratories
News and overview for Abbott Laboratories
J.P. Morgan, Intel, Abbott Laboratories in focus - MarketWatch
MarketWatch | 41 days 21 hours 4 minutes ago
See Europe Markets for more.See Asia Markets for more.
MarketWatch - Stock Market Quotes, Business News, Financial News
MarketWatch | 41 days 20 hours 56 minutes ago
Dollar down as retail sales beat estimates
Abbott to fund clinical study of Xience Prime stent
AdvaMed SmartBrief | 1 day 4 hours 6 minutes ago
Abbott Laboratories will sponsor a clinical trial that will compare the efficacy of its Xience Prime stent with coronary artery bypass graft surgery...
Abbott reports 37% spike in third-quarter profit - MarketWatch
MarketWatch | 41 days 21 hours 20 minutes ago
The health-care-products conglomerate posted net income of $1.48 billion, or 95 cents a share, compared with $1.09 billion, or 69 cents a share, for the same quarter in 2008.
Abbott reports 37% spike in third-quarter earnings - MarketWatch
MarketWatch | 41 days 21 hours 52 minutes ago
ABT
Abbott Labs leads drug stocks higher - MarketWatch
MarketWatch | 41 days 20 hours 7 minutes ago
Oil hits one-year high on higher stocks, dollar
Abbott, Sanofi lead drug stocks higher - MarketWatch
MarketWatch | 41 days 19 hours 49 minutes ago
Shares of Abbott /quotes/comstock/13*!abt/quotes/nls/abt (ABT 50.93, +1.28, +2.58%) were up almost 2% to $50.51.
Abbott's Meridia undergoes FDA safety review
FMI Pharmacy dailyLead | 2 days 4 hours 6 minutes ago
The FDA is evaluating data linking Abbott Laboratories' obesity drug Meridia to an increased risk of heart attack, stroke and other cardiovascular events. The drug has been available since 1997, but the FDA recommends against its use in patients with heart-related conditions.
Medtronic Second Quarter Revenue Increases 8% to $3.838 Billion; Raises EPS Guidance for Current Fiscal Year [Press Release]
Business Wire | 21 hours 51 minutes ago
Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2010, which ended Oct. 30, 2009.
Research and Markets: Genetic Testing - A Global Update of Market Trends & Opportunities [Press Release]
Business Wire | 19 hours 6 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/a3cde6/genetic_testing) has announced the addition of the "Genetic Testing - A Global Update of Market Trends & Opportunities" report to their offering.
Four Senior Executives Join Orexigen(R) Therapeutics Management Team [Press Release]
PRNewswire | 1 day 15 hours 6 minutes ago
...President and General Manager of Managed Care at Abbott Laboratories. Klassen will lead the global development program...Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing...
Abbott to buy rights to Dutch biotech firm's pain drug
BIO SmartBrief | 12 days 4 hours 6 minutes ago
Abbott Laboratories agreed to pay $190 million to acquire global rights to PanGenetics' PG110, an experimental pain treatment. Abbott officials said they hope to introduce injectable and intravenous versions of the drug, which is in Phase I trials.
Coldstream Laboratories, Inc. Names Vice President [Press Release]
MarketWire | 21 days 10 hours 57 minutes ago
LEXINGTON, KY -- (Marketwire) -- 11/03/09 -- Coldstream Laboratories, Inc. (CLI) is pleased to announce the addition of
Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets [Press Release]
Business Wire | 25 days 19 hours 21 minutes ago
Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.
Stocks in focus for Wednesday - MarketWatch
MarketWatch | 42 days 11 hours 23 minutes ago
The company appears to be riding its manufacturing engine on all cylinders, as well as benefiting from better demand for its computer chips.
Sign up for BIO SmartBrief
Company Overview
| Company: | Abbott Laboratories |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.abbott.com |
Filling baby bottles and soothing aching joints are a habit for Abbott. Abbott Laboratories is one of the US's top health care products makers. The company's pharmaceuticals include HIV treatment Norvir, rheumatoid arthritis therapy Humira, and obesity drug Meridia. Its nutritional products division makes such well-known brands as Similac infant formula and the Ensure line of nutrition supplements. Abbott also makes diagnostic instruments and tests, including the FreeStyle diabetes care line, as well as vascular and ocular medical devices. Its animal health division offers wound care, nutritional supplements, and IV supplies. The company sells its products in about 130 countries through affiliates and distributors.
Key Numbers
| Sales in U.S. Dollars (mil.) | 29,527.6 (2008) |
|---|---|
| One-year % Growth in Sales | 13.9 (2008) |
| Net Income in U.S. Dollars (mil.) | 4,880.7 (2008) |
| One-year % Growth in Net Income | 35.3 (2008) |
| Number of Employees | 69,000 (2008) |
| One-year % Growth in Number of Employees | 1.5 (2008) |
| Fiscal Year-End | December |